Recommended Free Tools
Cipla and Sun Pharma are both large Indian pharmaceutical companies, but their portfolios, reported growth and geographic exposures differ. In FY2024–25, Sun reported the larger revenue base and faster growth on its reported measures; Cipla reported growth across its One Africa business and South Africa operations. Their company disclosures also point to different mixes of pricing, policy, regulatory and execution risks. The figures below are company-reported, not a like-for-like investment assessment.
Which company is larger, and how did each perform?
Sun Pharma reported FY2024–25 consolidated revenue of ₹520 billion (₹52,000 crore), up 9.0% year over year. Its EBITDA was ₹153 billion, up 17.3%, and adjusted net profit was ₹120 billion, up 19.0%. These are Sun’s reported measures and definitions. Sun Pharma FY2024–25 Annual Report
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Made in India: The Story of Desh Bandhu Gupta, Lupin and Indian Pharma | $8.00 | Buy on Amazon |
As an Amazon Associate I earn from qualifying purchases.
Cipla reported FY2024–25 revenue from operations of ₹27,548 crore, up 7%. Its EBITDA was ₹7,128 crore, equal to a 25.9% EBITDA margin. Cipla FY2024–25 Annual Report
On reported revenue, Sun’s FY2024–25 business was larger. Growth rates also favor Sun in this period, but the profit measures and reporting presentations are not fully harmonized here; the figures do not by themselves establish which company is more profitable, resilient or attractively valued.
How do their businesses differ?
Cipla’s portfolio
Cipla groups its offerings into generics and branded generics, specialty medicines and consumer health. Its company page describes more than 4,000 partners in Indian generics and a fragmented market with more than 5,000 pharmaceutical players; these are company-provided descriptions. It also identifies uncertainty around trade margins, branded-generic policy, the Drug Price Control Order (DPCO) and product approvals. Cipla: Our Offerings
Cipla’s FY2024–25 reporting highlights portfolios including One India, North America, South Africa, and Emerging Markets and Europe. These labels describe the company’s business focus and should not be treated as directly comparable segment-revenue categories against Sun’s reporting.
Sun Pharma’s portfolio
Sun describes a portfolio spanning generic and branded medicines, patent-protected specialty medicines, over-the-counter (OTC) products, active pharmaceutical ingredients (APIs) and intermediates. Its product page lists specialty focus areas including dermatology, ophthalmology and oncology, and says the company operates in more than 100 countries. Sun Pharma: Our Product Portfolio
Sun reported that global specialty contributed 20% of consolidated revenue in FY2024–25, up from 18% in FY2024, and that specialty research and development spending was US$154 million in FY2024–25. These figures show the scale of its specialty emphasis; they do not establish the future returns on that investment. Sun Pharma FY2024–25 Annual Report
What do their geographic exposures show?
The following figures are selected examples, not matched measures of geographic diversification. They cover different markets and use different reporting bases.
| Company and market | FY2024–25 reported result | Basis |
|---|---|---|
| Cipla, One Africa | ₹3,827 crore revenue; 14% growth | Growth excludes the QCIL divestment. Cipla FY2024–25 Annual Report |
| Cipla, South Africa | ZAR 6.3 billion revenue; 15% growth | Growth in local currency. Cipla FY2024–25 Annual Report |
| Sun Pharma, India | ₹169,230 million revenue; 33% of revenue | Company-reported FY2024–25 figures. Sun Pharma FY2024–25 Annual Report |
| Sun Pharma, India market share | 8.3% | Based on AIOCD AWACS data for the 12 months ended March 2025. Sun Pharma FY2024–25 Annual Report |
Sun’s reported country reach and Cipla’s Africa growth illustrate different facets of international exposure, while Sun’s India figures show the importance of its domestic business. A broad footprint can diversify demand, but it also brings more markets, rules and operating conditions to manage. That is an analytical implication of the companies’ disclosures, not a measured comparison of their diversification.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.What business risks do the companies identify?
Pricing and competition
Sun’s management describes price erosion in parts of its generic business, including the US, and a more conservative approach in those markets. The report also discusses healthcare buyers seeking value. Cipla describes intense competition in India’s fragmented generics market and uncertainty around trade margins and policy. These are company-reported risk themes, not a quantified comparison of each company’s sensitivity to price changes. Sun Pharma FY2024–25 Annual Report; Cipla: Our Offerings
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Regulation and approvals
Cipla’s stated Indian-market concerns include DPCO, trade-margin rules, branded generics and product approvals. Sun says regulatory requirements vary across the countries in which it operates. The possible financial effect depends on the product and market; the cited disclosures do not quantify comparable exposure for the two companies. Cipla: Our Offerings; Sun Pharma FY2024–25 Annual Report
Supply chains and geopolitics
Sun’s annual report discusses pandemic-era medicine-availability disruptions, supply-chain changes, local sourcing and geopolitical uncertainty around reliable medicine supply. It also describes onshoring and nearshoring as broader industry trends. This identifies the kinds of operational pressures the company monitors; it is not evidence that either company is currently experiencing a particular shortage or disruption. Sun Pharma FY2024–25 Annual Report
Portfolio investment and execution
Sun presents specialty medicines as a strategic investment and growth priority. Cipla’s FY2024–25 report identifies investment areas including inhalation therapies, complex generics, peptide injectables, oligonucleotides and differentiated 505(b)(2) products. Developing and commercializing such products involves execution and market risks; the cited reports do not quantify the likelihood or financial impact of those outcomes. Sun Pharma FY2024–25 Annual Report; Cipla FY2024–25 Annual Report
How should readers compare them?
Start with the question that matters to you: overall scale, growth, domestic exposure, international reach, or the balance between established generics and specialty investment. For FY2024–25, Sun reported greater revenue and faster growth on its stated measures, while the selected geography figures show Cipla’s Africa growth and Sun’s sizable India business. Their portfolios and disclosures point to risks across pricing, regulation, supply and execution.
This is a comparison of company-reported business information, not a valuation or a recommendation to buy either company’s shares. The available figures do not provide a harmonized segment breakdown or comparable risk-sensitivity analysis, so they cannot support a definitive claim that one business is categorically safer or better.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
